Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Nab-paclitaxel, Liposomal Irinotecan +/- SHR-1701 in Neoadjuvant Pancreatic Cancer
NCT07806110Phase 2Active, not recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in pancreatic ductal adenocarcinoma (PDAC), sponsored by The First Hospital of Jilin University. Started Jul 2026; status: active, not recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07806110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806110.